HeartSciences Q1 FY2024: no revenue, $576K cash; MyoVista FDA submission targeted for late 2023

HeartSciences Inc.

2024-Q1 EPS reported -$0.13

No revenue for Q1 FY2024; cash and equivalents of $576K as of July 31, 2023.
Completed enrollment for MyoVista pivotal study; targeting FDA submission in late 2023.
Expanded IP portfolio to 41 patents (9 US, 32 international); appointed new distributors in Nordic and India.
Secured $15M equity line (March 2023) and $1M promissory note (Sept 2023) for funding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HeartSciences Inc. reported the first quarter fiscal 2024 ended July 31, 2023 results: revenue There were no revenues.

Period: the first quarter fiscal 2024 ended July 31, 2023
Revenue: There were no revenues
Result: reported results

Exact text from the filing

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-048186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.